Neuroprotective effects of D3 dopamine receptor agonists

Parkinsonism & Related Disorders
P M. CarveyZ D. Ling

Abstract

The effects of D(3) receptor activation are unresolved at this time, but may have practical implications in the treatment of Parkinson's disease (PD). As a result of assessing the neuroprotective effects of the direct-acting D(3) preferring dopamine (DA) agonist pramipexole (PPX), we have observed that drugs which psossess D(3) affinity increase the production of a DA neurotrophic factor in tissue culture. This molecule is increased by treatment with PPX, is constitutively produced by DA neurons in culture, and possesses a molecular weight of approximately 35kDa. It is hypothesized that this molecule may be the so-called DA autotrophic factor referred to by many authors over the past two decades. Interestingly, the protein is oxidant-labile and, therefore, D(3) agonists which increase its production and also possess antioxidant capacity would provide unique neuroprotective benefits to patients with PD. However, many questions remain. Although the data supporting this notion are strong, it is clear that other unknown characteristics of DA agonists, including increased production of anti-apoptotic proteins, are also involved. This manuscript will review this concept in the context of tissue culture strategies of neuroprotection. ...Continue Reading

References

Jun 1, 1991·Lancet·Y Agid
Nov 1, 1990·Experimental Neurology·K Steece-CollierJ R Sladek
Nov 1, 1993·Trends in Neurosciences·C W Olanow
Feb 1, 1995·Journal of Neuroscience Research·D J KaneD E Bredesen
Sep 1, 1993·Pharmacology, Biochemistry, and Behavior·P M CarveyJ Z Fields
Dec 1, 1995·Annals of Neurology·D E Bredesen
Jun 15, 1996·Annals of the New York Academy of Sciences·A D OwenC D Marsden
Jan 1, 1995·Journal of Neural Transmission. General Section·S DethyS Goldman
Jan 31, 1996·Neuroreport·B C SwarzenskiR D Todd
Jul 18, 1996·European Journal of Pharmacology·M GassenM B Youdim
Dec 1, 1996·Neurology·P Jenner, C W Olanow
Dec 1, 1996·Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration·P BongioanniM Castagna
Jan 1, 1997·Journal of Neural Transmission·P M CarveyZ D Ling
Jul 8, 1997·Proceedings of the National Academy of Sciences of the United States of America·S HunotE C Hirsch
Nov 22, 1997·Current Biology : CB·M HiltonA M Davies
Feb 6, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·O RascolF Stocchi
Mar 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·S ShimizuY Tsujimoto
Jun 13, 1998·American Journal of Human Genetics·W D Parker, R H Swerdlow
May 20, 1998·Proceedings of the National Academy of Sciences of the United States of America·D OffenO Bernard
Sep 2, 1998·Current Opinion in Neurology·S Przedborski, V Jackson-Lewis
Oct 2, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·H L RyooJ N Joyce
Jan 1, 1999·Amino Acids·P F VonVoigtlanderJ S Althaus
May 1, 1999·Journal of the Neurological Sciences·J P Bennett, M F Piercey
May 13, 1999·Drugs & Aging·T J Collier, C E Sortwell

❮ Previous
Next ❯

Citations

Aug 16, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·Dieter SchellerHermann Lübbert
Oct 16, 2003·Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP·H V Nobre JúniorV S N Rao
Jun 28, 2003·Neurotoxicity Research·Emilia Mabel GattoFederico E Micheli
Mar 23, 2010·International Clinical Psychopharmacology·Giorgio Racagni, Maurizio Popoli
Apr 11, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M R Lemke
Dec 6, 2011·Clinical Neurology and Neurosurgery·Shiroh MiuraTakayuki Taniwaki
Nov 26, 2005·The European Journal of Neuroscience·Fang DuWeidong Le
Jul 9, 2004·Annals of the New York Academy of Sciences·G GilleW-D Rausch
May 7, 2004·The European Journal of Neuroscience·Jackalina M Van KampenHarold A Robertson
Oct 21, 2010·Journal of Clinical Pharmacology·Michael E BozikEvan W Ingersoll
Jul 4, 2006·Journal of the Neurological Sciences·Matthias R LemkeHeinz Reichmann
Jun 29, 2004·Biological Psychiatry·Carlos A ZarateHusseini K Manji
Mar 31, 2009·Clinical and Experimental Hypertension : CHE·Chunyu ZengPedro A Jose
May 1, 2002·Expert Review of Neurotherapeutics·Gurutz J Linazasoro
Aug 30, 2013·International Journal of Molecular Sciences·Santiago CuevasInes Armando
Aug 25, 2018·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Bilge DoganLevent Sevincok
Dec 15, 2005·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Zhiwei YangPedro A Jose
Dec 18, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Chunyu ZengPedro A Jose
Apr 1, 2006·CNS Spectrums·Sanjay GuptaBradford Frank
Mar 16, 2017·Scientific Reports·Javier Castro-HernándezDavid I Finkelstein
Jul 2, 2003·Neurotoxicity Research·Justo Garcia De YébenesMaria Angeles Mena
Jul 9, 2003·Annals of the New York Academy of Sciences·Timothy J CollierCaryl E Sortwell
Dec 23, 2020·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Janine Naß, Thomas Efferth
Jan 24, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Diego Luis-RaveloTomas Gonzalez-Hernandez

❮ Previous
Next ❯

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.